Amicus director equity cashed out in BioMarin deal
AMICUS THERAPEUTICS director Michael Raab disposed of his equity in connection with the company’s acquisition by BioMarin Pharmaceutical.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
AMICUS THERAPEUTICS director Michael Raab disposed of his equity in connection with the company’s acquisition by BioMarin Pharmaceutical. The filing shows 115,857 shares of Common Stock were cancelled at $14.50 per share, with the cash value paid as part of the merger consideration.
Footnotes state this amount included 95,443 Common shares and 20,414 restricted stock units that fully vested at closing. Multiple fully vested stock options were also cancelled and converted into cash based on the $14.50 per-share merger price minus each option’s exercise price. After these transactions, Raab reported zero remaining direct holdings or outstanding options.
Insider Trade Summary
Disposition: 419,487 shares
Disposition
10 txns
Insider
RAAB MICHAEL
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Stock Options (right to buy) | 20,000 | $0.00 | $0.00 |
| Disposition | Stock Options (right to buy) | 16,236 | $0.00 | $0.00 |
| Disposition | Stock Options (right to buy) | 19,473 | $0.00 | $0.00 |
| Disposition | Stock Options (right to buy) | 18,574 | $0.00 | $0.00 |
| Disposition | Stock Options (right to buy) | 36,111 | $0.00 | $0.00 |
| Disposition | Stock Options (right to buy) | 45,423 | $0.00 | $0.00 |
| Disposition | Stock Options (right to buy) | 30,474 | $0.00 | $0.00 |
| Disposition | Stock Options (right to buy) | 42,467 | $0.00 | $0.00 |
| Disposition | Stock Options (right to buy) | 74,872 | $0.00 | $0.00 |
| Disposition | Common Stock | 115,857 | $14.50 | $1.68M |
Holdings After Transaction:
Stock Options (right to buy) — 0 contracts (Direct);
Common Stock — 0 shares (Direct)
Footnotes (4)
- F1. The reported securities were disposed of in connection with consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc. (the "Merger"), which included 95,443 shares of Common Stock and 20,414 restricted stock units (which vested in full in connection with consummation of the Merger).
- F2. In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option.
- F3. Each Option was fully vested.
- F4. Each Option vested in full in connection with consummation of the Merger.
Key Figures
Common shares cancelled: 115,857 shares at $14.50
Common shares component: 95,443 shares
RSUs vested and cancelled: 20,414 units
+5 more
8 metrics
Common shares cancelled
115,857 shares at $14.50
Common Stock cancelled for cash in BioMarin merger
Common shares component
95,443 shares
Portion of cancelled Common Stock noted in footnote
RSUs vested and cancelled
20,414 units
Restricted stock units vested and settled at merger closing
Option exercise price
$5.96 per share
One cancelled stock option series exercise price
Option exercise price
$10.27 per share
Another cancelled stock option series exercise price
Option exercise price
$12.62 per share
Another cancelled stock option series exercise price
Merger cash price
$14.50 per share
Cash consideration used to value stock and options
Post-transaction holdings
0 shares, 0 options
Director’s reported position after merger-related dispositions
Key Terms
restricted stock units, stock option, Merger, exercise price, +1 more
5 terms
restricted stock units financial
"20,414 restricted stock units (which vested in full in connection with consummation of the Merger)"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
stock option financial
"each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
Merger financial
"in connection with consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc. (the "Merger")"
A merger is when two companies combine into a single business, with ownership and control reorganized so they operate as one entity. For investors it matters because mergers can change the value and risk of holdings—shares may be exchanged, diluted, or rise if the combined company saves costs or gains market power, and the deal often depends on regulatory approval and successful integration like two households joining resources and routines.
exercise price financial
"equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
fully vested financial
"Each Option was fully vested."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Amicus Therapeutics (FOLD) director Michael Raab report in this Form 4?
Michael Raab reported the disposition of all his Amicus Therapeutics equity in connection with the BioMarin acquisition. His Common Stock, restricted stock units, and vested stock options were cancelled and converted into cash based on the agreed $14.50 per-share merger price.
What happened to Michael Raab’s stock options in Amicus Therapeutics (FOLD)?
Each of Michael Raab’s reported stock options was cancelled at the merger closing and converted into a cash payment. The cash amount equaled the excess of the $14.50 merger price over each option’s exercise price, multiplied by the number of underlying shares.
Is this Amicus Therapeutics (FOLD) Form 4 an open-market sale by the director?
No. The transactions are coded as dispositions to the issuer tied to the BioMarin merger. Securities were cancelled and converted into cash consideration at $14.50 per share, rather than sold in open-market trades, reflecting standard equity settlement at deal closing.
AI-generated analysis. How Rhea-AI works. Not financial advice.
